title: Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation.
abstract: T-cell depletion (TCD) of the bone marrow graft remains the most effective method to prevent severe graft versus host disease after allogeneic bone marrow transplantation. Early studies of HLA-identical sibling transplants showed that although T-cell depletion decreased GVHD, T-cell depleted transplants had higher risks of graft failure and leukemia relapse, leukemia free survival (LFS) was not improved compared to non-T-cell depleted transplants. In order to avoid graft failure and increased risk of relapse associated with this approach, we initiated a pilot study of T-cell depletion of the marrow graft combined with reinfusion of a fixed quantity of CD2+ peripheral blood T-cells. Depletion technique consisted in negative purging using CD2 and CD7 monoclonal antibodies (MoAbs) followed by rabbit complement cytolysis. This approach was associated with an intensified conditioning regimen using total body irradiation, high-dose cytosine arabinoside and melphalan (TAM) for all but one patient. Twenty-one patients were included with a mean age of 40 years. Only one acute severe Graft Versus Host Disease (GVHD) was observed and all patients engrafted. At 63 months, probability of survival is 42.86% with a relapse risk of 19.89%, two patients died from B-cell lymphoproliferative disease, seven other died from the procedure partially because of the use of the TAM as pretransplant regimen. This approach is being pursued by a gene therapy trial using herpes-simplex - 1 thymidine kinase gene expressing peripheral donor T-cells.
authors.affiliation: Service d'Hématologie, Centre Hospitalo-Universitaire de Besançon, France.
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: E
authors.initials: E
authors.lastname: Deconinck
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: A
authors.initials: A
authors.lastname: Brion
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: M
authors.initials: M
authors.lastname: Deschaseaux
authors.forename: R
authors.initials: R
authors.lastname: Angonin
authors.forename: L
authors.initials: L
authors.lastname: Voillat
authors.forename: J
authors.initials: J
authors.lastname: Vuillier
authors.forename: J
authors.initials: J
authors.lastname: Fontan
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: J M
authors.initials: JM
authors.lastname: Cordonnier
authors.forename: S
authors.initials: S
authors.lastname: Comparot
authors.forename: M C
authors.initials: MC
authors.lastname: Woronoff-Lemsi
authors.forename: P
authors.initials: P
authors.lastname: Hervé
mesh_terms: D000328:Adult; D000818:Animals; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D008212:Lymphocyte Depletion; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens